123 related articles for article (PubMed ID: 37864166)
1. Correction: Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study.
Pascual J; Panni T; Dell'Agnello G; Gonderten S; Novick D; Evers S
J Headache Pain; 2023 Oct; 24(1):142. PubMed ID: 37864166
[No Abstract] [Full Text] [Related]
2. Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study.
Pascual J; Panni T; Dell'Agnello G; Gonderten S; Novick D; Evers S
J Headache Pain; 2023 Jul; 24(1):88. PubMed ID: 37460942
[TBL] [Abstract][Full Text] [Related]
3. A real-world analysis of patient-reported outcomes in patients with migraine by preventive treatment eligibility status in the US and Europe.
Ford JH; Foster SA; Nichols RM; Tockhorn-Heidenreich A; Ye W; Jackson J; Cotton S
J Patient Rep Outcomes; 2020 Jul; 4(1):53. PubMed ID: 32632891
[TBL] [Abstract][Full Text] [Related]
4. Combining patient reported outcomes and EHR data to understand population level treatment needs: correcting for selection bias in the migraine signature study.
Stewart WF; Yan X; Pressman A; Jacobson A; Vaidya S; Chia V; Buse DC; Lipton RB
J Patient Rep Outcomes; 2021 Dec; 5(1):132. PubMed ID: 34921650
[TBL] [Abstract][Full Text] [Related]
5. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study.
Kawata AK; Shah N; Poon JL; Shaffer S; Sapra S; Wilcox TK; Shah S; Tepper SJ; Dodick DW; Lipton RB
Headache; 2021 Mar; 61(3):438-454. PubMed ID: 33594686
[TBL] [Abstract][Full Text] [Related]
6. [Satisfaction of the migraine patient attending neurology clinics: results of CIEN-mig project (II)].
Pascual J; Sánchez del Río M; Jiménez MD; Láinez-Andrés J; Mateos V; Leira R; Pozo-Rosich P; Guzmán-Quilo C
Rev Neurol; 2010 Jun; 50(11):641-5. PubMed ID: 20514635
[TBL] [Abstract][Full Text] [Related]
7. Treatment satisfaction with calcitonin gene-related peptide monoclonal antibodies as a new patient-reported outcome measure: A real-life experience in migraine.
López-Bravo A; Oliveros-Cid A; Sevillano-Orte L
Acta Neurol Scand; 2022 Jun; 145(6):669-675. PubMed ID: 35243611
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway.
Zhou Z; Urman R; Gill K; Park AS; Vuvu F; Patel LB; Lu J; Wade RL; Frerichs L; Bensink ME
J Headache Pain; 2023 Nov; 24(1):153. PubMed ID: 37946113
[TBL] [Abstract][Full Text] [Related]
9. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study.
Diamond S; Bigal ME; Silberstein S; Loder E; Reed M; Lipton RB
Headache; 2007 Mar; 47(3):355-63. PubMed ID: 17371352
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study.
Manack Adams A; Hutchinson S; Engstrom E; Ayasse ND; Serrano D; Davis L; Sommer K; Contreras-De Lama J; Lipton RB
J Headache Pain; 2023 Aug; 24(1):102. PubMed ID: 37537578
[TBL] [Abstract][Full Text] [Related]
11. [Preventive treatment with topiramate enhances the quality of life of patients with migraine].
Medrano V; Sempere AP; Morera-Guitart J; Fernandez-Izquierdo S; Espinosa-Martinez J
Rev Neurol; 2006 Sep 1-15; 43(5):259-63. PubMed ID: 16941422
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
13. Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study.
Barbanti P; Goadsby PJ; Lambru G; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B
J Headache Pain; 2022 Dec; 23(1):153. PubMed ID: 36460983
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study.
Lipton RB; Nicholson RA; Reed ML; Araujo AB; Jaffe DH; Faries DE; Buse DC; Shapiro RE; Ashina S; Cambron-Mellott MJ; Rowland JC; Pearlman EM
Headache; 2022 Feb; 62(2):122-140. PubMed ID: 35076091
[TBL] [Abstract][Full Text] [Related]
15. Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences.
Lipton RB; Munjal S; Alam A; Buse DC; Fanning KM; Reed ML; Schwedt TJ; Dodick DW
Headache; 2018 Oct; 58(9):1408-1426. PubMed ID: 30341895
[TBL] [Abstract][Full Text] [Related]
16. Treatment Satisfaction of Galcanezumab in Japanese Patients with Episodic Migraine: A Phase 2 Randomized Controlled Study.
Tatsuoka Y; Takeshima T; Ozeki A; Matsumura T
Neurol Ther; 2021 Jun; 10(1):265-278. PubMed ID: 33835383
[TBL] [Abstract][Full Text] [Related]
17. Prevalence Rates of Primary Headache Disorders and Evaluation and Treatment Patterns Among Korean Neurologists.
Kim BK; Chu MK; Yu SJ; Dell'Agnello G; Hundemer HP; Panni T; Alonso SP; Roche SL; Han JH; Cho SJ
J Clin Neurol; 2022 Sep; 18(5):571-580. PubMed ID: 36062775
[TBL] [Abstract][Full Text] [Related]
18. Care Among Migraine Patients in a Commercially Insured Population.
Bonafede M; McMorrow D; Noxon V; Desai P; Sapra S; Silberstein S
Neurol Ther; 2020 Jun; 9(1):93-103. PubMed ID: 32062840
[TBL] [Abstract][Full Text] [Related]
19. Migraine treatment patterns and patient satisfaction with prior therapy: a substudy of a multicenter trial of rizatriptan effectiveness.
Ceballos Hernansanz MA; Sanchez Roy R; Cano Orgaz A; López-Gil A;
Clin Ther; 2003 Jul; 25(7):2053-69. PubMed ID: 12946550
[TBL] [Abstract][Full Text] [Related]
20. Patients' preference for migraine preventive therapy.
Peres MF; Silberstein S; Moreira F; Corchs F; Vieira DS; Abraham N; Gebeline-Myers C
Headache; 2007 Apr; 47(4):540-5. PubMed ID: 17445103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
